{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"30.3","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Complete and Partial Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0","dispersionType":"90% Confidence Interval","groups":[{"description":"Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels","title":"Tumor Response","type":"PRIMARY","unitOfMeasure":"percentage of patients"}